Real-World Data on First-line Treatment of Hormone Receptor-positive, HER2-negative, Metastatic Breast Cancer in Brazil
This study aims to describe in detail the patient journey from diagnosis to the beginning of treatment and patterns of care of hormone receptor- positive, HER2-negative de novo or recurrent metastatic breast cancer between January 2018 and December 2020 in Brazil.
Breast Cancer
The proportion of type of first-line treatment, from January 2018 to December 2020
The PFS, defined as time from treatment start until progression (by image or physical exam) or death, from January 2018 to December 2020|First-line treatment according to the drug name by type of health care coverage (public vs private), from January 2018 to December 2020|The PFS will be evaluated by type of health care coverage (public vs private)., from January 2018 to December 2020|Timeline from first symptom to diagnosis, from January 2018 to December 2020|Timeline from diagnosis to molecular test, from January 2018 to December 2020|Timeline from diagnosis to the beginning of treatment, from January 2018 to December 2020|Patients' socioeconomic characteristics, from January 2018 to December 2020|Patients' demographics characteristics, from January 2018 to December 2020|BC pathological characterization, from January 2018 to December 2020|Rate of diagnostic tests to define breast cancer molecular subtypes performed, from January 2018 to December 2020
This study aims to describe in detail the patient journey from diagnosis to the beginning of treatment and patterns of care of hormone receptor- positive, HER2-negative de novo or recurrent metastatic breast cancer between January 2018 and December 2020 in Brazil.